

## Clinical Policy: Brand Name Override

Reference Number: CP.PMN.22

Effective Date: 09.01.06

Last Review Date: 02.26

Line of Business: Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### Description

Brand name drugs require review prior to approval. A generic drug is identical and bioequivalent to a brand name drug in dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use. Generic substitution is mandatory for Centene health plans when A-rated generic equivalents are available; however, brand name drugs may be approved in certain circumstances where there are adverse reactions to or therapeutic failure of generic drugs.

### FDA Approved Indication(s)

Varies by drug product.

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that non-preferred brand name drugs are **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria\*

*\* For members in Nevada, medical management techniques, including quantity management, beyond step therapy is not allowed for medication-assisted treatment (MAT)/withdrawal, HIV, and Hepatitis C drugs*

##### A. Request for Brand Name Drug in Lieu of Generic Formulation (must meet all):

1. Prescribed indication is FDA-approved;\*  
*\* Requests for off-label use should also be reviewed against CP.PMN.53 – Off-Label Use Policy*
2. Request is not for a benefit excluded use (e.g., cosmetic);
3. Failure of an adequate trial of or clinically significant adverse effects to two generics\* (each from a different manufacturer) or the preferred biosimilar(s) of the requested brand name drug, unless member has contraindications to the excipients in all generics/biosimilars;  
*\*If a second generic of the requested brand name drug is not available, member must try a formulary alternative that is FDA-approved or supported by standard pharmacopeias (e.g., DrugDex) for the requested indication, provided that such agent exists, unless request is for treatment of a member in a State with limitations on step therapy in certain settings (see Appendix E) or for treatment associated with cancer for a State with regulations against step therapy in certain oncology settings (see Appendix F)*
4. If clinically significant adverse effects were experienced to alternative therapies required in criterion 3 above, provider submits chart note documentation;

5. Provider submits clinical rationale\* supporting why the brand name drug will be more effective than the generic or will not produce the same adverse effects as the generic;  
*\*Use of a copay card or discount card does not constitute medical necessity*
6. Request meets one of the following (a or b):
  - a. Dose does not exceed the FDA approved maximum recommended dose for the relevant indication and health plan approved daily quantity limit;
  - b. Dose is supported by practice guidelines or peer-reviewed literature (*prescriber must submit supporting evidence*).

**Approval duration: 12 months**

**B. Request for Brand Name Drug When a Generic Equivalent Does Not Exist:**

1. Refer to Requests for Medically Necessary Drug Not on the PDL policy, CP.PMN.16.

**II. Continued Therapy\***

*\* For members in Nevada, medical management techniques, including quantity management, beyond step therapy is not allowed for medication-assisted treatment (MAT)/withdrawal, HIV, and Hepatitis C drugs*

**A. All Requests in Section I (must meet all):**

1. Member meets one of the following (a, b, or c):
  - a. Currently receiving medication via Centene benefit;
  - b. Member has previously met initial approval criteria;
  - c. State or health plan continuity of care programs apply to the requested drug and indication (e.g., seizures, heart failure, human immunodeficiency virus infection, and psychotic disorders [e.g., schizophrenia, bipolar disorder], oncology) with documentation that supports that member has received this medication for at least 30 days (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy;
3. If request is for a dose increase, request meets one of the following (a or b):
  - a. New dose does not exceed the FDA-approved maximum recommended dose for the relevant indication and health plan approved daily quantity limit;
  - b. New dose is supported by practice guidelines or peer-reviewed literature (*prescriber must submit supporting evidence*).

**Approval duration: 12 months**

**III. Diagnoses/Indications for which coverage is NOT authorized:** Not applicable

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

FDA: Food and Drug Administration

*Appendix B: Therapeutic Alternatives*

Varies by drug product

*Appendix C: Contraindications/Boxed Warnings*

Varies by drug product

*Appendix D: General Information*

- Examples of failure of a generic drug include:
  - Suboptimal drug plasma levels while taking the generic drug as compared to drug plasma levels while taking the brand name drug;
  - Increase or worsening in symptoms (e.g., increase in seizure activity) when switched to a generic drug that is not attributed to progression of the disease state, increase in member age or weight, or member non-compliance.

*Appendix E: States with Limitations against Redirections in Certain Settings*

State	Step Therapy Prohibited?	Notes
AR	Yes	For the treatment of psychosis and serious mental illness through antipsychotic prescription drugs, no step therapies allowed.
NV	No	For typical or atypical antipsychotic or anticonvulsant medications, step therapy is limited to one PDL drug.

*Appendix F: States with Regulations against Redirections in Cancer*

State	Step Therapy Prohibited?	Notes
FL	Yes	For stage 4 metastatic cancer and associated conditions.
GA	Yes	For stage 4 metastatic cancer. Redirection does not refer to review of medical necessity or clinical appropriateness.
IA	Yes	For standard of care stage 4 cancer drug use, supported by peer-reviewed, evidence-based literature, and approved by FDA.
IN	Yes	For advanced, metastatic cancer and associated conditions
LA	Yes <sup>‡</sup>	For stage 4 advanced, metastatic cancer or associated conditions. <sup>‡</sup> Exception if clinically equivalent therapy, contains identical active ingredient(s), and proven to have same efficacy.
MS	Yes	For advanced metastatic cancer and associated conditions
NV	Yes	Stage 3 and stage 4 cancer patients for a prescription drug to treat the cancer or any symptom thereof of the covered person
OH	Yes	For stage 4 metastatic cancer and associated conditions
OK	Yes	For advanced metastatic cancer and associated conditions
PA	Yes	For stage 4 advanced, metastatic cancer
TN	Yes <sup>^</sup>	For stage 4 advanced metastatic cancer, metastatic blood cancer, and associated conditions <sup>^</sup> Exception if step therapy is for AB-rated generic equivalent, interchangeable biological product, or biosimilar product to the equivalent brand drug
TX	Yes	For stage 4 advanced, metastatic cancer and associated conditions

**V. Dosage and Administration**

Varies by drug product

**VI. Product Availability**

Varies by drug product

**VII. References**

1. FDA Center for Drug Evaluation and Research (CDER) Orange Book Preface at <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079068.htm>. Accessed October 21, 2025.
2. FDA Electronic Orange Book at <http://www.fda.gov/cder/ob/>. Accessed October 21, 2025.
3. FDA MedWatch Reporting Forms at <http://www.fda.gov/Safety/MedWatch/HowToReport>. Accessed October 21, 2025.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
1Q 2022 annual review: no significant changes; references reviewed and updated.	10.19.21	02.22
Template changes applied to continued therapy section.	09.20.22	
1Q 2023 annual review: no significant changes; added the following clarification to chart note requirements of adverse effects: If clinically significant adverse effects were experienced <i>to alternative therapies required in criterion 2 above</i> , provider submits chart note documentation; references reviewed and updated.	10.27.22	02.23
Revised continuity of care verbiage to state: State or health plan continuity of care programs apply to the requested drug and indication (e.g., seizures, heart failure, human immunodeficiency virus infection, and psychotic disorders [e.g., schizophrenia, bipolar disorder], oncology) with documentation that supports that member has received this medication for at least 30 days.	03.14.23	
1Q 2024 annual review: added requirement that request is not for a benefit excluded use; references reviewed and updated.	10.23.23	02.24
Added disclaimer that medical management techniques, including quantity management, beyond step therapy is not allowed for members in NV per SB 439.	05.28.24	
1Q 2025 annual review: for redirection when a second generic of the requested brand name drug is not available, added bypass for States with regulations against redirection in certain settings, along with Appendix E and F; references reviewed and updated.	10.22.24	02.25
1Q 2026 annual review: no significant changes; references reviewed and updated.	10.21.25	02.26
For Appendix F, added states IN, MS, OH, and OK.	03.30.26	

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and

accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2006 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.